PACCRETA: clinical situations at high risk of placenta ACCRETA/percreta: impact of diagnostic methods and management on maternal morbidity
Gilles Kayem, Catherine Deneux-Tharaux, Loic Sentilhes, PACCRETA group, Elie Azria, Gaël Beucher, Marie Pierre Bonnet, Bernard Branger, Marie Hélène Bouvier Colle, Lionel Carbillon, Catherine Crenn Hébert, Corinne Dupont, Jeanne Fresson, Cyril Huissoud, Bruno Langer, Pierre Raynal, René Charles Rudigoz, Françoise Vendittelli, Norbert Winer, Olivier Morel, Franck Perrotin, Gilles Kayem, Catherine Deneux-Tharaux, Loic Sentilhes, PACCRETA group, Elie Azria, Gaël Beucher, Marie Pierre Bonnet, Bernard Branger, Marie Hélène Bouvier Colle, Lionel Carbillon, Catherine Crenn Hébert, Corinne Dupont, Jeanne Fresson, Cyril Huissoud, Bruno Langer, Pierre Raynal, René Charles Rudigoz, Françoise Vendittelli, Norbert Winer, Olivier Morel, Franck Perrotin
Abstract
Background: No population-based study has assessed the prevalence of placenta accreta, the predictive value of prenatal diagnostic examinations, the maternal morbidity associated with its management, or its psychological effects. Moreover, the technical resources necessary for the safest delivery of women at risk have not been clearly identified.
Objectives: The primary objectives are to identify individual risk factors, as well as factors associated with types of management and with the healthcare facilities for postpartum hemorrhage. Secondary objectives are to (i) determine the prevalence of placenta accreta among women at risk; (ii) assess the predictive value of ultrasound and MRI for the diagnosis of placenta accreta in this population; (iii) evaluate psychological impact and physical complications; and (iv) report maternal physical complications during the year after delivery.
Design: Population-based prospective observational study of pregnant women with a placenta inserted at a uterine scar.
Setting: A total of 182 centers in eight French regions, with 270 000 deliveries annually.
Methods: We expect to include 620 women at risk of placenta accreta in two years, of whom approximately 120 (20%) will have placenta accreta.
Main outcome measures: The primary outcome measure is severe maternal hemorrhage; secondary outcome measures are maternal morbidity and deaths, predictive value of ultrasound and MRI, and psychological evaluations at 6 and 12 months.
Conclusion: This study will be the first prospective population-based study to include women at risk of placenta accreta and to investigate incidence, prenatal detection, type of management, morbidity and maternal psychological consequences.
© 2013 The Authors Acta Obstetricia et Gynecologica Scandinavica © 2013 Nordic Federation of Societies of Obstetrics and Gynecology.
Source: PubMed